Trial results with HRR-deficient (with mutations in one of five HRR genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D) breast, ovarian, pancreatic, and prostate cancer patients revealed that, compared with first-generation PARPis, AZD5305 exhibited excellent safety and tolerability profiles and favorable PK and PD properties with a wide therapeutic index [100]. Here, RAD51D is linked to prostate cancer.